Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT04183582 Not yet recruiting - Clinical trials for Postnatal Depression

Behavioural Activation (BA) for Postnatal Depression in Blackpool

BA
Start date: December 2019
Phase: N/A
Study type: Interventional

Is Behavioural Activation feasible, acceptable and potentially effective for mothers experiencing post natal depression in Blackpool? Phase 1: A series of single case studies which aim to examine and refine a) the appropriateness of the programme to women in Blackpool b) the suitability of BA as part of a stepped-care approach to perinatal mental health within the Health Visitor pathway and c) the delivery of the programme in practice. Phase 2: A preliminary single group study examining the quantitative outcomes for participating women (i.e. symptoms of depression, anxiety and general mood, parental stress, responsiveness, and behavioural avoidance and activation.

NCT ID: NCT04183205 Recruiting - Clinical trials for Major Depressive Disorder

Predicting SSRI Efficacy in Veterans With PTSD

SSRI
Start date: September 11, 2019
Phase: Phase 4
Study type: Interventional

This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.

NCT ID: NCT04182061 Completed - Depressive Disorder Clinical Trials

Internet Transdiagnostic-CBT for Anxiety and Depression in Adolescents

Start date: November 15, 2019
Phase: N/A
Study type: Interventional

This study represents the first research program to assess the efficacy of transdiagnostic cognitive behavior therapy (T-CBT) delivered via internet for anxiety and depression in adolescents. The primary aim of the study was to implement the program AMTE (Aprende a Manejar tus Emociones [Learn to Manage Your Emotions]), an internet delivered T-CBT protocol designed to target both anxiety and depression symptoms and disorders (major depression disorder, dysthymic disorder, panic disorder, agoraphobia, generalized anxiety disorder, and social anxiety disorder) in adolescents, and to establish its preliminary efficacy on anxiety and depressive symptomatology. A secondary objective is to demonstrate its potential effect regarding: (a) transdiagnostic measures associated with etiology of emotional disorders including negative affect, anxiety sensitivity, and emotional avoidance, and (b) positive factors including satisfaction with life and positive affect. It is expected that the T-CBT condition will be more effective than the waitlist (WL) control group on the primary (anxiety and depression) and secondary (transdiagnostic and positive factors) outcome measures.

NCT ID: NCT04181736 Recruiting - Clinical trials for Major Depressive Disorder

The BIomarker Guided Study for Depression

BIG
Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

The diagnosis of major depression relies on patient reports, and two patients with the same diagnosis might share only one symptom. Thus, a single mechanism is unlikely to underlie a broad descriptive diagnosis such as major depression. Our approach is anchored by a neural circuit taxonomy that proposes distinct biotypes of depression derived from functional magnetic resonance imaging (fMRI) (Williams et al., 2016). In this study, we aim to target a putative type of major depression that arises from dysfunction in cognitive control neural circuitry with a drug called guanfacine.

NCT ID: NCT04181567 Completed - Clinical trials for Major Depressive Disorder

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

Start date: March 3, 2014
Phase: Phase 4
Study type: Interventional

Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants. The purpose of this study is to compare the efficacy, safety, and time to relapse/recurrence of ECT to ECT plus agomelatine in the treatment of patients with major depressive disorder. Inpatients with major depressive disorder for ECT will be randomly assigned to double-blind treatment with placebo or agomelatine 50 mg/d.

NCT ID: NCT04180683 Completed - Depression Clinical Trials

Comparison Study of the Different Abbreviated Versions of the Geriatric Depression Scale

Start date: March 1, 2020
Phase:
Study type: Observational

This multicenter study conducted in several Portuguese institutions aims to compare the screening ability of the several Geriatric Depression Scale (GDS) validated versions for the Portuguese population (GDS-30, GDS-15, GDS-10 and GDS-5), as well as to establish their psychometric properties, using a large sample of elderly people with neurocognitive disorders attending social responses addressed to the elderly. Secondarily, cognitive state will be assessed.

NCT ID: NCT04179526 Completed - Clinical trials for Major Depressive Disorder

Transdiagnostic Internet-delivered REBT Intervention for Adolescents' Internalizing Problems

REBTonAd
Start date: January 25, 2020
Phase: N/A
Study type: Interventional

To investigate the efficacy and mechanisms of change of an Internet-delivered transdiagnostic REBT intervention for adolescents with internalizing problems.

NCT ID: NCT04179006 Recruiting - Clinical trials for Depressive Disorder, Major

Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients

Start date: November 14, 2019
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, placebo-controlled to evaluate the potential role of nutrients supplementation (LF chocolate /Erinacine A-enriched Hericium Erinaceus chocolate) on the therapeutic efficacy of antidepressants in major depressive disorder(MDD). 120 subjects who meet all the inclusion and exclusion criteria will be randomized into three categories, receiving 3 pieces of supplement nutrients-added or plain chocolates per day for a period of 24 weeks in total. The three categories are as follow: 1. LF chocolate 2. Erinacine A-enriched Hericium Erinaceus chocolate 3. Plain chocolate without any supplementary nutrients added (placebo group) These MDD patients will continue their antidepressant regimen throughout the study. Symptom rating, blood samples for antidepressant-related/depressive disorder-related genome profiles identification, as well as for biomarkers assessment for metabolic indices, questionnaires and tests for psychosocial variables identification and patient's cognitive and social cognitive function or performance determination, will be carried out before and at certain time points within the 24-week tracking period. Patient's fecal samples will be acquired to recognize and to distinguish the alterations of these MDD patients microbiota profiles over the 24-week period.

NCT ID: NCT04177706 Completed - Depression Clinical Trials

Ketamine for the Treatment of Opioid Use Disorder and Depression

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

NCT ID: NCT04172974 Recruiting - Depression, Anxiety Clinical Trials

eHealth Intervention to Manage Depression and Anxiety in Patients With Ischemic Heart Disease

eMYHeart
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness and cost-effectiveness of a therapy-assisted internet-based intervention in patients with ischemic heart disease and co-morbid depression and anxiety referred for cardiac rehabilitation. Half of the patients will receive the intervention and the other half usual care. We hypothesize that the intervention will lead to a reduction in patients' symptoms of depression and anxiety and be cost-effective.